Item request has been placed!
×
Item request cannot be made.
×
Processing Request
C2 PHARMA opens research access to safety stock of Digoxin API for use in potential COVID-19 combination treatment.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
The article reports on announcement of C2 Pharma Sarl (C2P), chemical pharmaceutical manufacturing firm, which will open access to safety stocks and active pharmaceutical ingredient (API) Digoxin. Topics discussed incldue reduction of symptoms of COVID-19 patients due to API, Digoxin extracted from digitalis lanata plant, and safety stocks to ensure supply as standard operating procedure.
No Comments.